Vanta Bioscience (BOM:540729) Long-Term Debt: ₹312.08 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:540729 Vanta Bioscience Ltd BOM:540729
51 GF Score
Price ₹19.64
GF Value ₹11.76
Valuation Significantly Overvalued
! 9 Warning Signs
View Full Analysis

What is Vanta Bioscience Long-Term Debt?

Vanta Bioscience BOM:540729 51 Long-Term Debt is ₹312.08 Mil as of Mar. 2026. GuruFocus rates BOM:540729 with a GF Score™ of 51/100 and a GF Value™ of ₹11.76 (Significantly Overvalued). The stock has 9 warning signs investors should review.

Vanta Bioscience's Long-Term Debt for the quarter that ended in Mar. 2026 was ₹312.08 Mil.

Vanta Bioscience's quarterly Long-Term Debt declined from Mar. 2025 (₹541.25 Mil) to Sep. 2025 (₹230.08 Mil) but then increased from Sep. 2025 (₹230.08 Mil) to Mar. 2026 (₹312.08 Mil).

Vanta Bioscience's annual Long-Term Debt increased from Mar. 2024 (₹488.92 Mil) to Mar. 2025 (₹541.25 Mil) but then declined from Mar. 2025 (₹541.25 Mil) to Mar. 2026 (₹312.08 Mil).

Vanta Bioscience  (BOM:540729) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Vanta Bioscience Long-Term Debt Related Terms

Vanta Bioscience Long-Term Debt Historical Data

* Premium members only.

The historical data trend for Vanta Bioscience's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vanta Bioscience Long-Term Debt Chart

Vanta Bioscience Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Long-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 369.98 470.67 488.92 541.25 312.08

Vanta Bioscience Semi-Annual Data
Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 488.92 521.18 541.25 230.08 312.08
BOM:540729
51GF Score
Vanta Bioscience Ltd BOM:540729
Long-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Long-Term Debt →
What does a Long-Term Debt of ₹312.08 Mil mean?
Vanta Bioscience (BOM:540729) has a Long-Term Debt of ₹312.08 Mil as of Mar. 2026.
Is Vanta Bioscience's Long-Term Debt too high?
Vanta Bioscience's current Long-Term Debt is ₹312.08 Mil. Overall, Vanta Bioscience has a GF Score™ of 51/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Vanta Bioscience's Long-Term Debt compare to TMO and DHR?
Vanta Bioscience's Long-Term Debt of ₹312.08 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Debt for a Medical Diagnostics & Research company?
A good Long-Term Debt depends on the Medical Diagnostics & Research industry context. However, Long-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Debt mean?
A high Long-Term Debt can signal that a stock is expensive relative to its fundamentals. Vanta Bioscience's current Long-Term Debt is ₹312.08 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vanta Bioscience stock overvalued right now?
Based on GuruFocus' analysis, Vanta Bioscience (BOM:540729) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹11.76, compared to a current price of ₹19.64 — trading 67% above its estimated fair value. The current Long-Term Debt is ₹312.08 Mil. Vanta Bioscience's overall GF Score™ is 51/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Debt calculated?
Long-Term Debt is calculated from a company's financial statements. For Vanta Bioscience (BOM:540729), the current Long-Term Debt is ₹312.08 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Vanta Bioscience (BOM:540729) Overvalued in 2026?

Based on GuruFocus' analysis, Vanta Bioscience stock appears to be overvalued. The current stock price of ₹19.64 is trading 67% above its estimated GF Value™ of ₹11.76. GuruFocus considers Vanta Bioscience to be Significantly Overvalued.

Key valuation signals for BOM:540729:

  • Long-Term Debt: ₹312.08 Mil
  • GF Value™: ₹11.76 vs. price of ₹19.64 (67% above fair value)
  • GF Score™: 51/100 with 9 warning signs

No single metric tells the full story. See the BOM:540729 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Vanta Bioscience Business Description

Address No. 02/G/308/G, Umajay Complex, No. 3/FF/SF/1-20-248, Rasoolpura, Secunderabad, TG, IND, 500003
Vanta Bioscience Ltd is a full-service preclinical contract research organization based in Chennai, India, providing preclinical safety assessment services for the pharmaceutical, medical devices, nutraceuticals, biotech, agrochemicals, cosmetics, chemical, and feed additive industries. Established as a center of excellence in GLP-compliant toxicology and safety assessment, the company supports clients through toxicology studies, batch release tests, biocompatibility evaluations, agro-chemical and chemical safety assessments, and diet formulation services. It also offers testing and contract research services in clinical and pre-clinical research, biopharma studies, analytical testing, and environmental assessments.
51GF Score

Get the complete analysis for BOM:540729

Long-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹19.64
Price
₹11.76
GF Value